Boditech Med Signs MOU with Taiwan's BPM for Diabetic Kidney Disease Prediction Marker
- MOU signed for the license of diabetic kidney disease prediction marker 'DNlite-IVD103'.
- Over 40% of diabetic patients develop kidney-related complications.
- The transition from diagnosis to prevention in diabetic kidney disease is expected to occur rapidly.
Boditech Med, a leading point-of-care diagnostics company, announced on the 29th that it has signed a Memorandum of Understanding (MOU) with Taiwan's Bio Preventive Medicine Corp. (BPM) for the license of 'DNlite-IVD103', a biomarker for predicting diabetic kidney disease.
'DNlite-IVD103' is a diagnostic product designed to accurately monitor and prevent the deterioration of kidney function in diabetic patients. Unlike existing tests that focus on post-damage diagnosis, 'DNlite-IVD103' can detect signs of kidney damage up to five years earlier. This early detection allows for timely intervention and treatment before irreversible kidney damage occurs.
According to the International Diabetes Federation (IDF), over 500 million people worldwide were diagnosed with diabetes in 2021, a number expected to rise steadily to 784 million by 2045. More than 40% of diabetic patients suffer from kidney-related complications, with many progressing to end-stage renal disease requiring dialysis or kidney transplantation.
Diabetic kidney disease is anticipated to shift rapidly from the diagnosis phase to prevention, leading to a surge in demand for predictive diagnostic tools.
BPM holds proprietary antibody materials, core technologies, and global patents related to 'DNlite-IVD103'. Through this agreement, Boditech Med will be the first to launch a point-of-care diagnostic product for the 'DNlite-IVD103' marker worldwide. Development will proceed using two existing point-of-care platforms: ichroma and AFIAS.
Boditech Med CEO Eui-Yeol Choi stated, "Diabetes is one of the top three global health issues. 'DNlite-IVD103' is a product that can monitor the risk of chronic kidney disease in diabetic patients through a simple urine test. Following the launch of the AFIAS penKid® diagnostic product for acute kidney injury in September last year, this agreement completes our diagnostic lineup covering both acute and chronic kidney injuries."
Boditech Med's website：Boditech Med Signs MOU with Taiwan's BPM for Diabetic Kidney Disease Prediction Marker
Medi Consumer News website：Boditech launches world's first diabetic kidney disease prediction biomarker product